Evercore ISI downgraded Augmedix to In Line from Outperform with a price target of $1.50, down from $5, following an in-line Q1 print and “disappointing” guidance. Management pointed to “the realization of many of our risks regarding the company and market,” including delayed decision making, increased competition, cannibalization of Live by Go Assist, and a delay in the HCA rollout, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix Inc (AUGX) Q1 Earnings Cheat Sheet
- Augmedix to Participate in Upcoming Investor Conferences in May and June 2024
- Augmedix announces general availability of Augmedix Go
- Augmedix upgraded to Outperform from In Line at Evercore ISI
- Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care